海外の治験の状況「1」での検索結果
65件の検索結果
- 進捗状況
- 試験名
- 対象疾患名
- 地域
- 登録日
Not Available
- Efficacy and safety of thalidomide in pediatric patients with Crohn's disease
- Crohn's Disease MedDRA version: 19.0 Level: LLT Classification code 10011402 Term: Crohn's disease (colon) System Organ Class: 100000004856 ;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
- Italy
- 2016-11-30
Not Available
- A phase 1/2 study of the investigational treatment LOXO-195 in adults and minors that have a previously treated cancer with a change in a gene called NTRK.
- NTRK fusion cancers previously treated with a TRK inhibitor MedDRA version: 20.0 Level: LLT Classification code 10049516 Term: Malignant tumor System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) MedDRA version: 20.0 Level: PT Classification code 10007958 Term: Central nervous system neoplasm System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Diseases [C] - Cancer [C04]
- Australia, Denmark, France, Germany, Italy, Korea, Republic of, Singapore, Spain, United States
- 2018-01-23
Not Available
- Pharmacocinétique de population des anti-infectieux (Ceftazidime, Ciprofloxacine et Voriconazole) chez l’enfant âgé de 1 mois à 5 ans. - PHARM-A
- Anti-infectieux en pédiatrie : étude des paramètres pharmacocinétiques de trois anti-infectieux couramment prescrits en pédiatrie et dans des pathologies différentes : mucoviscidose ; infections à pseudomonas ; patients immunodéprimés fébriles ; patients de réanimation ; septicémies à Candida ; mycoses ....
- France
- 2011-03-28
Not Available
- Treatment of proteinuria with angiotensin-converting enzyme inhibitor in children after renal transplantation
- proteinuria and hypertension MedDRA version: 9.1 Level: LLT Classification code 10037032 Term: Proteinuria
- Czech Republic
- 2006-12-19
Not Available
- Gene Therapy for Crigler Najjar Syndrome
- severe Crigler Najjar syndrome in patients requiring phototherapy MedDRA version: 20.0 Level: PT Classification code 10011386 Term: Crigler-Najjar syndrome System Organ Class: 10010331 - Congenital, familial and genetic disorders ;Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]
- France, Netherlands
- 2018-01-18
Not Available
- A Phase 3 Study of an Investigational Drug, Lumasiran (ALN-GO1) with an Extended Dosing Period in Children and Adults with Primary Hyperoxaluria Type 1 Disease
- Primary Hyperoxaluria Type 1 (PH1) MedDRA version: 20.1 Level: PT Classification code 10020703 Term: Hyperoxaluria System Organ Class: 10038359 - Renal and urinary disorders ;Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]
- France, Germany, Israel, Japan, Jordan, Netherlands, Switzerland, United Arab Emirates, United States
- 2018-09-11
Not Available
- Phase II Multicenter, Open-label, Clinical and Pharmacokinetic Study of Zalypsis® (PM00104) in Patients with Unresectable Locally Advanced and/or Metastatic Ewing Family of Tumors (EFT) Progressing After at Least One Prior Line of Chemotherapy. Étude de phase II , multicentrique, ouverte, clinique et pharmacocinétique de Zalypsis® (PM00104) chez des patients atteints d’un sarcome de la famille des tumeurs d’Ewing (EFT) non resécable, localement avancé et/ou métastatique en progression après au moins une première ligne chimiothérapique
- Advanced and/or Metastatic Ewing Family of Tumors (EFT) MedDRA version: 12.1 Level: LLT Classification code 10057846 Term: Primitive neuroectodermal tumour MedDRA version: 12.1 Level: LLT Classification code 10015560 Term: Ewing's sarcoma MedDRA version: 12.1 Level: LLT Classification code 10015759 Term: Extra-osseous Ewing's sarcoma MedDRA version: 12.1 Level: LLT Classification code 10057656 Term: Askin's tumour
- France, Italy
- 2010-10-11
Not Available
- Study to compare the immunogenicity of GlaxoSmithKline Biologicals' thiomersal-free 2-dose Engerix™-B and 3-dose preservative-free Engerix™-B vaccines administered according to a 0, 6 month and 0, 1, 6 month schedule, respectively, and to evaluate safety and reactogenicity of each vaccine in healthy adolescent volunteers (11 to 15 years).
- Hepatitis B vaccination of healthy adolescents.;Therapeutic area: Diseases [C] - Virus Diseases [C02]
- Australia, Ukraine
- 2015-06-26
Not Available
- Study to evaluate the immunogenicity, safety, and reactogenicity of TWINRIX ADULT containing 720 ELISA units of hepatitis A antigen and 20 µg of hepatitis B surface antigen, administered following a two-dose (0, 6 months) schedule in healthy children between the ages of 1 and 11 years.
- To protect healthy male and female children aged 1 to 11 years old included against hepatitis A and B. ;Therapeutic area: Diseases [C] - Virus Diseases [C02]
- Belgium
- 2015-06-10
Not Available
- Study to compare the immunogenicity, safety and reactogenicity of SmithKline Beecham’s Twinrix administered following a 2 dose schedule (0, 6 months) to that of Twinrix Junior administered following a 3 dose schedule (0, 1, 6 months) in healthy volunteers aged 12-15 years.
- To protect healthy volunteers between the ages of 12 and 15 years against hepatitis A and hepatitis B viruses and to determine the optimal dose range and schedule of the combined hepatitis A / hepatitis B vaccine, with respect to immunogenicity, reactogenicity and safety in this age group.;Therapeutic area: Diseases [C] - Virus Diseases [C02]
- Belgium, Czech Republic
- 2015-06-03
